Showing results (291-300 of 372) with videos related to

Sort By:
Pageof 38
Molecular Cancer Therapeutics|April 8, 2011
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trialMonika E Hegi, Annie-Claire Diserens, Pierre Bady, et al.
Cancer Research|January 17, 2009
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomasBalasubramanian Sivasankaran, Martin Degen, Anthony Ghaffari, et al.
Acta Neuropathologica|August 14, 2012
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiao-Yang Liu, Noha Gerges, Andrey Korshunov, et al.
The Lancet. Oncology|August 30, 2024
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect groupPhilipp Karschnia, Jasper K W Gerritsen, Nico Teske, et al.
Journal of Neuro-Oncology|July 7, 2022
Mid-term treatment-related cognitive sequelae in glioma patientsSabine Schlömer, Jörg Felsberg, Milena Pertz, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
Acta Neuropathologica|October 21, 2015
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityAndrey Korshunov, David Capper, David Reuss, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
Brain Pathology (Zurich, Switzerland)|February 19, 2017
Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelinationAlonso Barrantes-Freer, Aylin Sophie Engel, Odir Antonio Rodríguez-Villagra, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2021
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?Dorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
Pageof 38